Wegovy vs Mounjaro: Key Differences for UK Patients
Should I Switch From Mounjaro to Wegovy Based on UK Stock Availability?
The decision of whether you should switch from Mounjaro to Wegovy often centres on consistent supply availability, and this concern is now addressed with our reliable UK stock levels. Unlike previous months when Wegovy faced significant supply constraints, EverydayMeds maintains full inventory across all five dose strengths with direct supply agreements from Novo Nordisk. Our GPhC-registered pharmacy (#9012878) processes orders within standard timelines, ensuring you won't face treatment gaps that could impact your weight management progress.
Both medications are prescription-only medicines requiring clinical assessment, but they work through different mechanisms that may suit different patient profiles. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors as a dual agonist. Your prescriber can evaluate factors like your response to current treatment, any side effects experienced, and practical considerations like storage requirements when determining if switching from Mounjaro to Wegovy aligns with your healthcare goals.
Wegovy Pricing and Value When Switching From Mounjaro
Understanding the cost implications when considering whether you should switch from Mounjaro to Wegovy helps inform your decision alongside clinical factors. Wegovy starter doses begin at £79.99 for the 0.25mg pen (applied after FIRST40 discount for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the maintenance 2.4mg dose. Returning customers benefit from the DOSE25 discount code applied at checkout to achieve these final pricing levels.
Our bundled options provide convenience for patients establishing consistent supply, such as the Intro Duo (0.25mg and 0.5mg) for £169.99 or the Gentle Start Trio (0.25mg, 0.25mg, 0.5mg) for £269.99 for those preferring gradual dose escalation. The Ultimate Stability Trio offers three months of maintenance supply at 2.4mg for £649.99, ensuring treatment continuity. These bundles eliminate the need for multiple orders and assurance consistent supply during your treatment journey, particularly valuable if you're switching from Mounjaro to Wegovy and want to avoid any supply uncertainties.
Clinical Evidence Supporting the Switch From Mounjaro to Wegovy
When evaluating whether you should switch from Mounjaro to Wegovy, clinical trial data provides important context, though both medications have different study populations and endpoints that prevent direct comparison. The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events amongst patients taking semaglutide.
Both medications must be prescribed alongside a reduced-calorie diet and increased physical activity, and individual responses may vary significantly. Your prescriber will consider your current treatment response, medical history, and any side effects when determining if switching from Mounjaro to Wegovy might offer clinical advantages for your specific situation.
How Wegovy Works Differently From Mounjaro
Understanding the mechanistic differences helps clarify whether you should switch from Mounjaro to Wegovy based on how each medication functions in your body. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which regulates blood sugar and appetite. This targeted approach works on specific brain appetite centres to reduce food cravings and promote feelings of fullness after smaller meals. The medication slows gastric emptying, helping you feel satisfied for longer periods after eating. Unlike Mounjaro's dual-receptor approach, Wegovy's focused GLP-1 action may suit patients who respond well to this specific pathway or experience particular side effects with dual-agonist treatments.
Ordering Process When Switching From Mounjaro to Wegovy
The process for obtaining Wegovy when considering whether you should switch from Mounjaro begins with our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our prescribers review your assessment within 3 working days (or 24 hours with express service), considering your previous treatment experience and reasons for potential switching. Once approved, your Wegovy pens are dispatched via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. The entire process typically completes within one working week, ensuring minimal disruption to your treatment schedule. Our clinical team can coordinate timing to avoid gaps between your current Mounjaro supply and new Wegovy prescription.
Storage and Practical Advantages of Switching From Mounjaro to Wegovy
Practical considerations often influence decisions about whether you should switch from Mounjaro to Wegovy, particularly regarding storage requirements and travel convenience. Wegovy must be stored in the fridge at 2-8°C before first use but offers a significant advantage with 6 weeks of room temperature storage below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design provides precise dose delivery with clear markings, and the weekly injection schedule remains consistent with most GLP-1 treatments. Dose escalation follows a structured 16-week pathway from 0.25mg to the maintenance 2.4mg dose, allowing gradual tolerance development. This extended room temperature stability makes Wegovy particularly suitable for patients with active lifestyles, frequent travel, or limited reliable refrigeration access.
Supply Chain Reliability When Considering Switching From Mounjaro to Wegovy
Supply chain stability represents a crucial factor when determining whether you should switch from Mounjaro to Wegovy, given the historical shortages that affected Wegovy availability throughout 2023 and early 2024. EverydayMeds has established robust supply agreements directly with Novo Nordisk, ensuring consistent stock levels across all five dose strengths with regular replenishment schedules. Our inventory management systems monitor stock levels daily, providing early warning of any potential supply constraints that could affect patient treatment continuity.
We maintain strategic stock reserves and prioritise existing patients when allocating available doses during any temporary supply fluctuations. This supply chain investment means patients switching from Mounjaro to Wegovy can rely on consistent medication access without the treatment interruptions that previously characterised Wegovy availability. Our automated reorder reminders and subscription services further ensure seamless treatment continuation once you've established your maintenance dose.
Making Your Decision: Next Steps for Switching From Mounjaro to Wegovy
Ultimately, whether you should switch from Mounjaro to Wegovy depends on multiple factors including your current treatment response, side effect profile, practical considerations, and prescriber recommendations based on your individual medical situation. Both medications are available through EverydayMeds with reliable supply chains, competitive pricing, and comprehensive support services to ensure treatment success. Our clinical assessment process considers your previous treatment experience and can facilitate smooth transitions between medications when clinically appropriate. Use discount codes FIRST40 for new customers or DOSE25 for returning patients applied at checkout, and begin your assessment at https://everydaymeds.co.uk/collections/wegovy to explore your options with our qualified prescribers. Remember that weight management represents a long-term commitment requiring ongoing medical supervision, lifestyle modifications, and consistent medication adherence regardless of which prescription-only medicine best suits your needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
